Oramed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ORMP)

$8.70 0.09 (1.05 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$8.61
Today's Range$8.55 - $8.74
52-Week Range$5.82 - $11.34
Volume12,181 shs
Average Volume43,115 shs
Market Capitalization$125.46 million
P/E RatioN/A
Dividend YieldN/A
Beta0.34

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ORMP
CUSIPN/A
Phone972-2566-0001

Debt

Debt-to-Equity RatioN/A
Current Ratio3.93%
Quick Ratio3.93%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.45 million
Price / Sales50.82
Cash FlowN/A
Price / CashN/A
Book Value$1.44 per share
Price / Book6.04

Profitability

Trailing EPS($0.96)
Net Income$-10,480,000.00
Net Margins-426.93%
Return on Equity-49.77%
Return on Assets-25.40%

Miscellaneous

Employees12
Outstanding Shares14,310,000

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

When will Oramed Pharmaceuticals make its next earnings announcement?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, January, 10th 2018. View Earnings Estimates for Oramed Pharmaceuticals.

Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2017?

2 brokers have issued 1-year price objectives for Oramed Pharmaceuticals' stock. Their predictions range from $20.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $22.50 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:

  • Kevin L. Rakin, Chairman of the Board, Independent Director (Age 57)
  • Nadav Kidron, President, Chief Executive Officer, Director (Age 43)
  • Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
  • Joshua Hexter, Chief Operating Officer, Vice President - Business Development (Age 46)
  • Miriam Kidron Ph.D., Chief Scientific Officer, Director (Age 76)
  • Ronald Edward Law, Chief Strategy Officer (Age 64)
  • Aviad Friedman, Independent Director (Age 45)
  • Xiaopeng Li, Independent Director (Age 33)
  • Leonard Sank, Independent Director (Age 52)
  • David Slager, Independent Director (Age 44)

Who owns Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.14%). Company insiders that own Oramed Pharmaceuticals stock include Miriam Kidron, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals.

Who bought Oramed Pharmaceuticals stock? Who is buying Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Nadav Kidron and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals.

How do I buy Oramed Pharmaceuticals stock?

Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $8.70.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $125.46 million and generates $2.45 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Oramed Pharmaceuticals employs 12 workers across the globe.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 972-2566-0001 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oramed Pharmaceuticals (NASDAQ:ORMP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.33$22.00$22.00$22.00
Price Target Upside: 173.22% upside119.56% upside162.53% upside162.53% upside

Oramed Pharmaceuticals (NASDAQ:ORMP) Consensus Price Target History

Price Target History for Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017B. RileyReiterated RatingBuy -> Buy$20.00LowView Rating Details
11/22/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00N/AView Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00N/AView Rating Details
5/18/2016AegisReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Oramed Pharmaceuticals (NASDAQ:ORMP) Earnings Estimates

2018 EPS Consensus Estimate: ($1.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 2.03%
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Xiaopeng LiDirectorBuy89,636$8.50$761,906.00View SEC Filing  
4/19/2017Miriam KidronInsiderSell52,814$6.33$334,312.62View SEC Filing  
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines

Source:
DateHeadline
Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per ShareOramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - December 13 at 10:26 AM
Oramed Pharmaceuticals (ORMP) "Buy" Rating Reaffirmed at B. RileyOramed Pharmaceuticals' (ORMP) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - December 11 at 10:10 PM
B.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.comB.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.com
www.streetinsider.com - December 11 at 4:44 PM
ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to SellValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell
www.americanbankingnews.com - December 5 at 10:12 PM
Heres Why And How Oramed Pharmaceuticals Is Going After NASHHere's Why And How Oramed Pharmaceuticals Is Going After NASH
www.benzinga.com - November 28 at 4:31 PM
Oramed Pharmaceuticals (ORMP) "Buy" Rating Reiterated at HC WainwrightOramed Pharmaceuticals' (ORMP) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 22 at 8:40 AM
 Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00 Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - November 20 at 10:32 AM
Reviewing Oramed Pharmaceuticals (ORMP) and Its PeersReviewing Oramed Pharmaceuticals (ORMP) and Its Peers
www.americanbankingnews.com - November 19 at 9:26 PM
Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its RivalsCritical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals
www.americanbankingnews.com - November 19 at 3:30 PM
FDA Nod For AZNs Asthma Drug, Genmab Revises Outlook, NBY Disappoints - NasdaqFDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints - Nasdaq
www.nasdaq.com - November 15 at 7:10 AM
Oramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.comOramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.com
www.streetinsider.com - November 15 at 7:10 AM
Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin CapsuleOramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
finance.yahoo.com - November 15 at 7:10 AM
Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral ProteinsOramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins
www.streetinsider.com - November 2 at 7:22 AM
Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.comOramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.com
www.streetinsider.com - November 1 at 7:18 AM
Oramed Granted Broad Composition of Matter Patent in Europe for Oral ProteinsOramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
finance.yahoo.com - November 1 at 7:18 AM
Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - October 30 at 4:02 AM
Oramed to Present at the Diabetes Technology MeetingOramed to Present at the Diabetes Technology Meeting
finance.yahoo.com - October 25 at 8:42 AM
Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its ScientistsOramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its Scientists
www.streetinsider.com - October 18 at 1:50 AM
Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.comOramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.com
www.streetinsider.com - October 17 at 3:45 PM
Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed ScientistsEndocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists
finance.yahoo.com - October 17 at 3:45 PM
Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)
www.americanbankingnews.com - October 7 at 6:28 PM
HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)
www.americanbankingnews.com - October 5 at 3:38 PM
Oramed to Present at the Disruptive Growth Showcase ConferenceOramed to Present at the Disruptive Growth Showcase Conference
finance.yahoo.com - October 2 at 9:19 PM
Oramed Now Has a Clear Path to Market With Oral InsulinOramed Now Has a Clear Path to Market With Oral Insulin
finance.yahoo.com - September 23 at 9:12 AM
Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - September 12 at 2:26 AM
Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801
www.streetinsider.com - September 6 at 7:16 AM
Oramed Announces Successful Meeting with FDA for Oral InsulinOramed Announces Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM
Oramed (ORMP): Successful Meeting with FDA for Oral InsulinOramed (ORMP): Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM
Oramed to Present at the Rodman & Renshaw Global Investment ConferenceOramed to Present at the Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 30 at 7:40 AM
Oramed Pharmaceuticals Inc. (ORMP) Expected to Announce Quarterly Sales of $610,000.00Oramed Pharmaceuticals Inc. (ORMP) Expected to Announce Quarterly Sales of $610,000.00
www.americanbankingnews.com - August 17 at 9:48 AM
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in StockOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in Stock
www.americanbankingnews.com - August 3 at 7:52 PM
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expected to Post Quarterly Sales of $610,000.00Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - July 29 at 7:21 AM
 Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.28 Per Share Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - July 27 at 8:10 PM
Oramed Pharma (ORMP) CFO Resigns - StreetInsider.comOramed Pharma (ORMP) CFO Resigns - StreetInsider.com
www.streetinsider.com - July 22 at 7:22 AM
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs - PR Newswire (press release)Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs - PR Newswire (press release)
www.prnewswire.com - July 19 at 1:09 AM
Oramed Appoints Dr. Simon Bruce as Vice President of Medical AffairsOramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
finance.yahoo.com - July 19 at 1:09 AM
Oramed to Present at BITS 5th World Congress of Diabetes on July 13, 2017Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
finance.yahoo.com - July 13 at 7:42 AM
ORMP To Meet With FDA, Second Times No Charm For OCUL, Panel Backs PFEORMP To Meet With FDA, Second Time's No Charm For OCUL, Panel Backs PFE
www.rttnews.com - July 12 at 6:42 AM
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 ProgramOramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
finance.yahoo.com - July 12 at 6:42 AM
Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017
finance.yahoo.com - July 11 at 6:25 AM
Head to Head Review: Oramed Pharmaceuticals (ORMP) vs. ImmunoGen (IMGN)Head to Head Review: Oramed Pharmaceuticals (ORMP) vs. ImmunoGen (IMGN)
www.americanbankingnews.com - July 10 at 10:28 PM
Oramed reports 3Q lossOramed reports 3Q loss
finance.yahoo.com - July 7 at 7:54 AM
Oramed Announces Dual-Listing on Tel Aviv Stock ExchangeOramed Announces Dual-Listing on Tel Aviv Stock Exchange
finance.yahoo.com - July 5 at 9:21 AM
Oramed to Present at the American Diabetes Association 77th Scientific Sessions - PR Newswire (press release)Oramed to Present at the American Diabetes Association 77th Scientific Sessions - PR Newswire (press release)
www.prnewswire.com - June 6 at 7:49 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for - PR Newswire (press release)
www.prnewswire.com - June 5 at 7:40 PM
Oramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul - StreetInsider.comOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul - StreetInsider.com
www.streetinsider.com - May 10 at 11:49 AM
Oramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog CapsulOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul
www.streetinsider.com - May 9 at 11:16 AM
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule - PR Newswire (press release)Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule - PR Newswire (press release)
www.prnewswire.com - May 2 at 11:10 AM
Oramed Pharma (ORMP) Says EPO Granted Patent for Combination Oral Insulin and GLP-1 Analog Capsule - StreetInsider.comOramed Pharma (ORMP) Says EPO Granted Patent for Combination Oral Insulin and GLP-1 Analog Capsule - StreetInsider.com
www.streetinsider.com - April 21 at 12:12 AM
Oramed reports 2Q lossOramed reports 2Q loss
marketbeat.com - April 6 at 5:04 AM

SEC Filings

Oramed Pharmaceuticals (NASDAQ:ORMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oramed Pharmaceuticals (NASDAQ:ORMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oramed Pharmaceuticals (NASDAQ ORMP) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.